Increased Urinary Phosphate Excretion in Pseudohypoparathyroidism Type II with Long-Term Treatment with Phosphodiesterase Inhibitor
| Autor: | T. Kobahashi, Keiko Uchimura, Mitsuyasu Itoh, Toshiki Mano, Kentaro Fujiwara, Akio Nagasaka, R Hayashi, Mutsuko Nagata, Masaki Makino, A. Nakai, M. Wada, Hiroaki Kakizawa |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Nifedipine Phosphodiesterase Inhibitors Endocrinology Diabetes and Metabolism Urinary system Clinical Biochemistry Biochemistry Phosphates Excretion chemistry.chemical_compound Endocrinology Theophylline Internal medicine Cyclic AMP medicine Humans Phosphodiesterase inhibitor Pseudohypoparathyroidism Bucladesine Reabsorption Biochemistry (medical) General Medicine Calcium Compounds Middle Aged Calcium Channel Blockers Phosphate medicine.disease chemistry Lactates Calcium Female medicine.drug |
| Zdroj: | Hormone and Metabolic Research. 31:602-605 |
| ISSN: | 1439-4286 0018-5043 |
| DOI: | 10.1055/s-2007-978804 |
| Popis: | A 58-year-old woman was diagnosed to have pseudohypoparathyroidism (PHP) type II because of the absence of an increase of urinary phosphate secretion, despite a marked increase in urinary cAMP excretion on the Ellsworth-Howard test. We treated the patient with a cyclic-nucleotide phosphodiesterase inhibitor, theophylline, resulting in increased urinary phosphate and cAMP excretions. Dibutyl cAMP administration induced the increase in the urinary phosphate excretion. In this case, the unresponsiveness of the urinary phosphate secretion to cAMP was recovered by a high dose of cAMP or long-term administration of a phosphodiesterase inhibitor. These data imply that cAMP responsiveness to renal tubular phosphate reabsorption should be more strictly elucidated in the patient with PHP type II. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|